

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8	JAN 30	Saved answer limit increased
NEWS	9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14	FEB 28	TOXCENTER reloaded with enhancements
NEWS	15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16	MAR 01	INSPEC reloaded and enhanced
NEWS	17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18	MAR 08	X.25 communication option no longer available after June 2006
NEWS	19	MAR 22	EMBASE is now updated on a daily basis
NEWS	20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 06:54:08 ON 17 APR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 06:56:01 ON 17 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 APR 2006 HIGHEST RN 880516-92-7

DICTIONARY FILE UPDATES: 14 APR 2006 HIGHEST RN 880516-92-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	1.07

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 06:56:06 ON 17 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 07:31:33 ON 17 APR 2006

FILE 'REGISTRY' ENTERED AT 07:31:33 ON 17 APR 2006

COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION



FULL ESTIMATED COST

0.44

1.07

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10537346\10537346 clm 1 generic.str



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 18 19 20

chain bonds :

1-2 2-3 3-4 3-20 4-5 4-18 5-6 6-19 7-8 7-13 8-9 10-11 10-14 11-12

exact/norm bonds :

1-2 4-5 4-18 5-6 6-19 7-8 7-13 8-9 10-11 10-14

exact bonds :

2-3 3-4 3-20 11-12

G1:[*1],[*2]

Match level :



1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 18:CLASS 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 [C1], [C2]

Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam

SAMPLE SEARCH INITIATED 07:32:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 79 TO ITERATE

100.0% PROCESSED 79 ITERATIONS

45 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1047 TO 2113

PROJECTED ANSWERS: 498 TO 1302

L2 45 SEA SSS SAM L1

=> d scan


L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-(1-naphthalenyl)-, 2-(2-methylpropyl)-2-(methylsulfonyl)hydrazide, (2R,3S,5E)-(9CI)

MF C26 H37 N3 O5 S

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1-Imidazolidinebutanoic acid, β -[(hydroxyamino)carbonyl]-3,4,4-trimethyl- α -(2-methylpropyl)-2,5-dioxo-, 2-[(methylamino)carbonyl]-2-(phenylmethyl)hydrazide, (α R, β R)-(9CI)

MF C24 H36 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


IN 1-Piperidineacetic acid, 2-[(2R,3S,5E)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenyl-5-hexenyl]-1-(2-methylpropyl)hydrazide, mono(4-methylbenzenesulfonate) (salt) (9CI)

MF C28 H44 N4 O4 . C7 H8 O3 S


CM 1

Absolute stereochemistry.

Double bond geometry as shown.




CM 2



L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 3-Furancarboxylic acid, 2-[(2R,3S,5E)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenyl-5-hexenyl]-1-(2-methylpropyl)hydrazide (9CI)
 MF C26 H35 N3 O5


Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-,
 2-[[3-(diethylamino)propyl]sulfonyl]-2-(2-methylpropyl)hydrazide,
 (2R,3S,5E)- (9CI)
 MF C28 H48 N4 O5 S
 CI COM

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzenebutanoic acid, α -[(formylhydroxyamino)methyl]-,
 2-[(phenylamino)carbonyl]hydrazide (9CI)
 MF C19 H22 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 6-Quinolinecarboxylic acid, 1,2,3,4-tetrahydro-1-(hydroxyacetyl)-,
 2-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxoheptyl]hydrazide (9CI)
 MF C21 H30 N4 O6


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Benzofurancarboxylic acid, 2,3-dihydro-, 2-[(2R)-2-
 [(formylhydroxyamino)methyl]-1-oxoheptyl]hydrazide (9CI)
 MF C18 H25 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Heptanoic acid, 2-[(formylhydroxyamino)methyl]-, 2-[(2,3-dihydro-1,4-
 benzodioxin-2-yl)methyl]hydrazide, (2R)- (9CI)
 MF C18 H27 N3 O5

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-,
 2-[(2S)-2,4-diamino-1,4-dioxobutyl]-2-(2-methylpropyl)hydrazide,
 (2R,3S,5E)- (9CI)
 MF C25 H39 N5 O5
 CI COM

Absolute stereochemistry.


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzenehexanoic acid, β -[(hydroxyamino)carbonyl]- α -(2-methylpropyl)-, 2-[(dimethylamino)acetyl]-2-(phenylmethyl)hydrazide, (α R, β S)- (9CI)
 MF C28 H40 N4 O4
 CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzenebutanoic acid, β -[(hydroxyamino)carbonyl]- α -(2-methylpropyl)-, 2-(2-methylpropyl)-2-(methylsulfonyl)hydrazide, (α R, β S)- (9CI)
 MF C20 H33 N3 O5 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pentanoic acid, 2-[(1S)-2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-,
 2-[(methylamino)carbonyl]-2-(phenylmethyl)hydrazide, (2R)- (9CI)
 MF C18 H28 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-,
 2-[(2S)-2-amino-1-oxopropyl]-2-(2-methylpropyl)hydrazide,
 monohydrochloride, (2R,3S,5E)- (9CI)
 MF C24 H38 N4 O4 . Cl H

Absolute stereochemistry.
 Double bond geometry as shown.




● HCl


L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1H-1,2,3-Triazole-1-acetic acid, 2-[(2R,3S)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenylhexyl]-1-(phenylmethyl)hydrazide, mono(4-methylbenzenesulfonate) (salt) (9CI)
 MF C28 H36 N6 O4 . C7 H8 O3 S

CM 1

Absolute stereochemistry.




CM 2




L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1H-1,2,3-Triazole-1-acetic acid, 2-[(2R,3S)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenylhexyl]-1-[(2S)-2-methylbutyl]hydrazide (9CI)
 MF C26 H40 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Heptanoic acid, 2-[(formylhydroxyamino)methyl]-, 2-butyl-2-[[4,5-dihydro-3,5-dimethyl-4-isoxazolyl]amino]carbonyl]hydrazide (9CI)
 MF C19 H35 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1H-Benzimidazole-2-carboxylic acid, 2-[(2R)-2-[(formylhydroxyamino)methyl]-1-oxoheptyl]hydrazide (9CI)
 MF C17 H23 N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzeneacetic acid, 2-[3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hydrazide (9CI)
MF C18 H25 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Heptanoic acid, 2-[(formylhydroxyamino)methyl]-, 2-[(2-methoxyphenyl)methyl]hydrazide, (2R)- (9CI)
MF C17 H27 N3 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-[(2S)-2-(methylamino)-1-oxopropyl]-2-(2-methylpropyl)hydrazide, (2R,3S,5E)- (9CI)
MF C25 H40 N4 O4
CI COM

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):file caplus
'FILE CAPLUS' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.32

1.95

FILE 'CAPLUS' ENTERED AT 07:33:04 ON 17 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2006 VOL 144 ISS 17

FILE LAST UPDATED: 16 Apr 2006 (20060416/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 12

L3

7 L2

=> d 13 5-7 ti fbib abs

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of the release of tumor necrosis factor

AN 2000:15165 CAPLUS

DN 132:78850
 TI Preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as
 inhibitors of the release of tumor necrosis factor
 IN Broadhurst, Michael John; Johnson, William Henry; Walter, Daryl Simon
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 171 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000000465	A1	20000106	WO 1999-EP4223	19990617
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 1998-13919	A 19980626
				GB 1998-26491	A 19981202
US	6239151	B1	20010529	US 1999-332809	19990614
				GB 1998-13919	A 19980626
				GB 1998-26491	A 19981202
CA	2335245	AA	20000106	CA 1999-2335245	19990617
				GB 1998-13919	A 19980626
				GB 1998-26491	A 19981202
				WO 1999-EP4223	W 19990617
AU	9947737	A1	20000117	AU 1999-47737	19990617
AU	753660	B2	20021024		
				GB 1998-13919	A 19980627
				GB 1998-26491	A 19981202
				WO 1999-EP4223	W 19990617
BR	9911588	A	20010320	BR 1999-11588	19990617
				GB 1998-13919	A 19980627
				GB 1998-26491	A 19981202
				WO 1999-EP4223	W 19990617
EP	1089964	A1	20010411	EP 1999-931098	19990617
EP	1089964	B1	20031029		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
				GB 1998-13919	A 19980626
				GB 1998-26491	A 19981202
				WO 1999-EP4223	W 19990617
TR	200003731	T2	20010621	TR 2000-200003731	19990617
				GB 1998-13919	A 19980626
				GB 1998-26491	A 19981202
JP	2002519339	T2	20020702	JP 2000-557226	19990617
				GB 1998-13919	A 19980626
				GB 1998-26491	A 19981202
				WO 1999-EP4223	W 19990617
AT	253043	E	20031115	AT 1999-931098	19990617
				GB 1998-13919	A 19980626
				GB 1998-26491	A 19981202
				WO 1999-EP4223	W 19990617
PT	1089964	T	20040331	PT 1999-931098	19990617
				GB 1998-13919	A 19980626
				GB 1998-26491	A 19981202
ES	2209460	T3	20040616	ES 1999-931098	19990617
				GB 1998-13919	A 19980626
				GB 1998-26491	A 19981202

ZA 2000007320

A

20010621

ZA 2000-7320


20001208

GB 1998-13919

A 19980626

OS MARPAT 132:78850

GI



AB Tile hydrazides I [R1 = alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl; R2 is an acyl group derived from an α -, β -, γ - or δ -(amino, hydroxy or thiol) carboxylic acid in which the amino, hydroxy or thiol group is optionally lower alkylated or the amino group is optionally acylated, sulfonylated or amidated and in which any functional group present in a side-chain is optionally protected, or a group of the formula Het(CH₂)_mCO (Het is heterocyclyl, m = 0-4); R3 = H, alkyl, haloalkyl, cyanoalkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxyalkylalkyl, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, heterocyclylcarbonylalkyl, alkenyl, alkynyl, cycloalkyl, arylalkenyl, aryl or heterocyclyl; R4 = alkyl, alkenyl, cycloalkyl, cycloalkyl alkyl or a grouping of the formula X-aryl, X-heteroaryl or (CH₂)_n-CH=CR₅R₆, where R₅ and R₆ together are alkylene in which one CH₂ group is optionally replaced by a hetero atom, X is a spacer group, and n is 1 or 2] and their pharmaceutically acceptable salts were prepared as inhibitor of the release of tumor necrosis factor- α (TNF- α) from cells. Thus, (E)-2'-(D-alanyl)-2(R)-[1(S)-(hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-4-methylvalerohydrazide was prepared via reaction of N-(9-fluorenylmethoxycarbonyl)-D-alanine acid chloride with hydrazide derivative and shown to have IC₅₀ = 303 nMol for inhibition of TNF- α .

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of novel azapeptide type hydroxamic acid derivatives having a TNF α production inhibitory effect
AN 1999:511132 CAPLUS
DN 131:157991
TI Preparation of novel azapeptide type hydroxamic acid derivatives having a TNF α production inhibitory effect
IN Sugiyama, Naoki; Yoshida, Tomohiro; Takeda, Shinji; Maeda, Kazuhiro; Gotou, Tomokazu; Takemoto, Tadahiro
PA Yoshitomi Pharmaceutical Industries, Ltd., Japan
SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940063	A1	19990812	WO 1999-JP439	19990203
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9922983	A1	19990823	JP 1998-25664	A	19980206
			AU 1999-22983		19990203
			JP 1998-25664	A	19980206
			WO 1999-JP439	W	19990203

OS MARPAT 131:157991
GI



AB Disclosed are azapeptide type hydroxamic acid derivs. represented by general formula [I; wherein X represents hydrogen or a hydroxyl-protective group; R1 represents hydrogen, hydroxy, amino, mercapto, alkoxy, alkyl, alkenyl, aryl or $-(CH_2)_k-A$; wherein A represents (un)substituted 5- or 6-membered N-heterocyclyl; k = 1-4; R2 represents hydrogen, (un)substituted alkyl or aryl; R3 represents hydrogen, (un)substituted alkyl, aryl, or heteroaryl or $-(CONH)m-(CHR_{11})_n-Y$; wherein R11 represents hydrogen or (un)substituted alkyl; m is 0 or 1; n is 0-4; Y represents CO_2R_{12} , $CONR_{12}R_{12}'$, or COR_{12} [wherein R12 and R12' represent hydrogen, (un)substituted alkyl or aryl or $NR_{12}R_{12}$ forms (un)substituted heterocyclyl]; and R4 represents alkyl, aryl, heteroaryl, $-SO_2R_{12}$, $-CO-(CH_2)_q-NR_{12}R_{12}'$, $-CONH-Z-R_{13}$ or $-(CONH)m-(CHR_{11})_n-Y$, or R3 and R4 may together form a nitrogen-containing heterocycle; wherein R11, Y, m, R12, and R12' are same above; Z represents C2-4 alkylene; R13 represents hydroxy, amino, or $NR_{12}R_{12}'$] or pharmacol. acceptable salts thereof and medicinal compns. containing the same. Because of having a $TNF\alpha$ (tumor necrosis factor- α) production inhibitory effect, these compds. are useful in preventing and treating autoimmune diseases, inflammatory diseases, etc., for example, sepsis, MOF (multiple organ failure), chronic rheumatoid arthritis, Crohn's disease, cachexia, severe adynamia, systemic lupus erythematosus, asthma, type I diabetes and psoriasis. Thus, N-[4-hydroxy-(2R)-isobutylsuccinyl]aza-(2-naphthyl)alanyl-L-alanine benzyl ester was condensed with hydroxylamine hydrochloride using BPO reagent and 4-methylmorpholine in pyridine to give 58% N-[4-(N'-hydroxyamino)-(2R)-isobutylsuccinyl]aza-(2-naphthyl)alanyl-L-alanine benzyl ester which underwent amidation with $MeNH_2$ in MeOH at room temperature for 30 min to give 33% N-[4-(N'-hydroxyamino)-(2R)-isobutylsuccinyl]aza-(2-naphthyl)alanyl-L-alanine N''-methylamide. In an ELISA assay, the title compound (II) in vitro showed IC_{50} of $0.53 \mu M$ for inhibiting the production of $TNF\alpha$ in THP-1 cells.

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of tumor necrosis factor and transforming growth factor

release.
AN 1999:42740 CAPLUS
DN 130:110060
TI Preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of tumor necrosis factor and transforming growth factor release.
IN Broadhurst, Michael John; Johnson, William Henry; Walter, Daryl Simon
PA F. Hoffmann-La Roche A.-G., Switz.
SO Ger. Offen., 64 pp.
CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19829229	A1	19990107	DE 1998-19829229	19980630
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
	US 6235787	B1	20010522	US 1998-98235	19980616
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
	CA 2295062	AA	19990114	CA 1998-2295062	19980618
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
				WO 1998-EP3683	W 19980618
	WO 9901428	A1	19990114	WO 1998-EP3683	19980618
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
	AU 9886273	A1	19990125	AU 1998-86273	19980618
	AU 725039	B2	20001005		
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
				WO 1998-EP3683	W 19980618
	EP 993442	A1	20000419	EP 1998-937498	19980618
	EP 993442	B1	20030423		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
				WO 1998-EP3683	W 19980618
	TR 9903281	T2	20000921	TR 1999-9903281	19980618
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
	BR 9810952	A	20000926	BR 1998-10952	19980618
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
				WO 1998-EP3683	W 19980618
	JP 2000513750	T2	20001017	JP 1999-506230	19980618
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
				WO 1998-EP3683	W 19980618
	AT 238277	E	20030515	AT 1998-937498	19980618
				GB 1997-13833	A 19970630
				GB 1998-3335	A 19980217
				WO 1998-EP3683	W 19980618

PT 993442	T	20030930	PT 1998-937498	19980618
			GB 1997-13833	A 19970630
			GB 1998-3335	A 19980217
ES 2195365	T3	20031201	ES 1998-937498	19980618
			GB 1997-13833	A 19970630
			GB 1998-3335	A 19980217
ZA 9805469	A	19981230	ZA 1998-5469	19980623
			GB 1997-13833	A 19970630
IT 1301792	B1	20000707	IT 1998-MI1441	19980624
			GB 1997-13833	A 19970630
			GB 1998-3335	A 19980217
FR 2765219	A1	19981231	FR 1998-8124	19980626
FR 2765219	B1	19991029		
			GB 1997-13833	A 19970630
			GB 1998-3335	A 19980217
GB 2326881	A1	19990106	GB 1998-14027	19980629
			GB 1997-13833	A 19970630
			GB 1998-3335	A 19980217
ES 2140348	A1	20000216	ES 1998-1359	19980629
ES 2140348	B1	20001016		
			GB 1997-13833	A 19970630
			GB 1998-3335	A 19980217
MX 9911668	A	20000531	MX 1999-11668	19991214
			GB 1997-13833	A 19970630
			GB 1998-3335	A 19980217
			WO 1998-EP3683	W 19980618
BG 104050	A	20001229	BG 1999-104050	19991228
			GB 1997-13833	A 19970630
			GB 1998-3335	A 19980217
			WO 1998-EP3683	W 19980618
NO 9906534	A	20000223	NO 1999-6534	19991229
			GB 1997-13833	A 19970630
			GB 1998-3335	A 19980217
			WO 1998-EP3683	W 19980618

OS MARPAT 130:110060
GI



AB Title compds. [I; Y = CO, SO₂; R₁ = alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl; R₂ = alkyl, haloalkyl, aralkyl, aralkenyl, aryl, alkoxy, alkoxy carbonyl, etc.; R₃ = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aralkyl, aralkenyl, aryl, heterocyclyl; R₂R₃ = 5-7 membered cyclic amide, imide, sulfonamide, or urethane; R₄ = alkyl, alkenyl, cycloalkylalkyl, ArX, HetX, etc.; Ar = aryl; Het = heteroaryl; X = spacer], were prepared Thus, (E)-2(R)-[1(S)-(hydroxycarbonyl)-4-phenyl-3-butenyl]-2'-(methanesulfonyl)-4-methyl-2'-phenylvalerohydrazide (multistep preparation given) inhibited TNF α and TGF α release with IC₅₀ = 437 nM and 210 nM, resp.

=> save temp l3 cmpdanswers/a
ANSWER SET L3 HAS BEEN SAVED AS 'CMPDANSWRS/A'

=> logoff hold
COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST	ENTRY 10.52	SESSION 12.47
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 07:35:54 ON 17 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3 AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8 SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12 OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19	E-mail format enhanced
NEWS 14 OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16 OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17 OCT 30	CHEMLIST enhanced with new search and display field
NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 06:37:57 ON 31 OCT 2006

=>

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 06:38:14 ON 31 OCT 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'HOME' AT 06:41:44 ON 31 OCT 2006

FILE 'HOME' ENTERED AT 06:41:44 ON 31 OCT 2006

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 06:42:05 ON 31 OCT 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'HOME' AT 06:58:22 ON 31 OCT 2006

FILE 'HOME' ENTERED AT 06:58:22 ON 31 OCT 2006

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.26	1.26

FILE 'REGISTRY' ENTERED AT 07:00:41 ON 31 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 OCT 2006 HIGHEST RN 911633-89-1
DICTIONARY FILE UPDATES: 30 OCT 2006 HIGHEST RN 911633-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10537346\10537346 clm 1 correct genus.str



chain nodes :
 1 2 3 4 7 8 9 10 11 12 13 14 18 19 20
 ring nodes :
 5 6 21
 chain bonds :
 1-2 2-3 3-4 3-20 4-5 4-18 6-19 7-8 7-13 8-9 10-11 10-14 11-12
 ring bonds :
 5-6 5-21 6-21
 exact/norm bonds :
 1-2 4-5 4-18 5-6 5-21 6-19 6-21 7-8 7-13 8-9 10-11 10-14
 exact bonds :
 2-3 3-4 3-20 11-12

G1:[*1],[*2]

G2:C,O,S,N

Match level :



1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 18:CLASS 19:CLASS 20:CLASS
 21:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 [@1],[@2]

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam

SAMPLE SEARCH INITIATED 07:01:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5 TO 234

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search l1 sss full

FULL SEARCH INITIATED 07:01:33 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 144 TO ITERATE

100.0% PROCESSED 144 ITERATIONS

45 ANSWERS

SEARCH TIME: 00.00.01

L3 45 SEA SSS FUL L1

=> d scan


L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-

[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-phenyl- (9CI)

MF C21 H30 N4 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):45

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]- (9CI)
 MF C27 H40 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(4-pyridinylcarbonyl)- (9CI)
 MF C19 H26 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]-N-(2-methoxyphenyl)- (9CI)
 MF C21 H30 N4 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-
 oxopropyl]-2-(2-furanylcarbonyl)hexahydro- (9CI)
 MF C19 H27 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(3-furanylcarbonyl)hexahydro- (9CI)
 MF C19 H27 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-(2,4-difluorophenyl)tetrahydro- (9CI)
 MF C21 H28 F2 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(2-furanylcarbonyl)- (9CI)
 MF C18 H25 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(4-methoxybenzoyl)- (9CI)
 MF C21 H29 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]-N-(3-methoxyphenyl)- (9CI)
 MF C21 H30 N4 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-
 oxopropyl]hexahydro-2-[4-(trifluoromethyl)benzoyl]- (9CI)
 MF C22 H28 F3 N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-[[6-(4-morpholinyl)-3-pyridinyl]carbonyl]- (9CI)
 MF C24 H35 N5 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-(2-methoxyphenyl)- (9CI)
 MF C22 H32 N4 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-[4-(trifluoromethyl)benzoyl]- (9CI)
 MF C21 H26 F3 N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(3-pyridinylcarbonyl)- (9CI)
 MF C19 H26 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinebutanamide, β -(cyclopentylmethyl)-2-(2-furanylcarbonyl)tetrahydro-N-hydroxy- γ -oxo-, (β R)- (9CI)
 MF C19 H27 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-(4-methoxybenzoyl)- (9CI)
 MF C22 H31 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-(3-methoxyphenyl)-
 (9CI)
 MF C22 H32 N4 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1-Pyrazolidinecarboxylic acid, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI)
 MF C18 H31 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-(cyclohexylcarbonyl)-2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]- (9CI)
 MF C20 H33 N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]-N-phenyl- (9CI)
 MF C20 H28 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-(methoxyacetyl)- (9CI)
 MF C17 H29 N3 O5


Absolute stereochemistry.



. **PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(4-fluorobenzoyl)hexahydro- (9CI)
 MF C21 H28 F N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-[4-
 (trifluoromethyl)phenyl]- (9CI)
 MF C22 H29 F3 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-
 oxopropyl]-2-(methoxyacetyl)- (9CI)
 MF C16 H27 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-(1,3-benzodioxol-5-ylcarbonyl)-2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]- (9CI)
 MF C21 H27 N3 O6


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]-N-[4-(trifluoromethyl)phenyl]-
 (9CI)
 MF C21 H27 F3 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-(4-pyridinylcarbonyl)- (9CI)
 MF C20 H28 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro- (9CI)
 MF C23 H28 F6 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-N-methyl-N-phenyl-
 (9CI)
 MF C22 H32 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-
 oxopropyl]-2-(phenylacetyl)- (9CI)
 MF C21 H29 N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-2-(3-furanylcarbonyl)- (9CI)
 MF C18 H25 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinebutanamide, β -(cyclopentylmethyl)tetrahydro-N-hydroxy- γ -oxo-2-[(phenylamino)carbonyl]-, (BR)- (9CI)
 MF C21 H30 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-(1,3-benzodioxol-5-ylcarbonyl)-2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro- (9CI)
 MF C22 H29 N3 O6


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]-N-(4-fluorophenyl)tetrahydro-
 (9CI)
 MF C21 H29 F N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinecarboxylic acid, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]tetrahydro-, 1,1-dimethylethyl
 ester (9CI)
 MF C19 H33 N3 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-
 oxopropyl]-2-[[6-(4-morpholinyl)-3-pyridinyl]carbonyl]- (9CI)
 MF C23 H33 N5 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]-N-(4-fluorophenyl)- (9CI)
 MF C20 H27 F N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-benzoyl-2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-
 1-oxopropyl]hexahydro- (9CI)
 MF C21 H29 N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro-2-(phenylacetyl)- (9CI)
 MF C22 H31 N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1(2H)-Pyridazinecarboxamide, 2-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-oxopropyl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)tetrahydro- (9CI)
 MF C23 H32 N4 O6


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-benzoyl-2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]- (9CI)
 MF C20 H27 N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyrazolidine, 1-[(2R)-3-cyclopentyl-2-[(formylhydroxyamino)methyl]-1-
 oxopropyl]-2-(4-fluorobenzoyl)- (9CI)
 MF C20 H26 F N3 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1-Pyrazolidinecarboxamide, 2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]-N-methyl-N-phenyl- (9CI)
 MF C21 H30 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 45 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pyridazine, 1-(cyclohexylcarbonyl)-2-[(2R)-3-cyclopentyl-2-
 [(formylhydroxyamino)methyl]-1-oxopropyl]hexahydro- (9CI)
 MF C21 H35 N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

168.64

FILE 'CAPLUS' ENTERED AT 07:02:08 ON 31 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Oct 2006 VOL 145 ISS 19

FILE LAST UPDATED: 30 Oct 2006 (20061030/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> l3

L4 1 L3

=> d l4 ti fbib abs it

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of acylpyridazines and acylpyrazolidines as antibacterial agents.

AN 2004:493687 CAPLUS

DN 141:54351

TI Preparation of acylpyridazines and acylpyrazolidines as antibacterial agents.

IN East, Stephen Peter

PA Vernalis (Oxford) Ltd., UK

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050638	A1	20040617	WO 2003-GB5179	20031201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				GB 2002-28365	A 20021205
AU	2003285545	A1	20040623	AU 2003-285545	20031201
				GB 2002-28365	A 20021205
				WO 2003-GB5179	W 20031201
EP	1567504	A1	20050831	EP 2003-778542	20031201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
				GB 2002-28365	A 20021205
				WO 2003-GB5179	W 20031201
US	2006128811	A1	20060615	US 2006-537346	20060123
				GB 2002-28365	A 20021205
				WO 2003-GB5179	W 20031201

OS MARPAT 141:54351

AB QCHR1CHR2CONR3NR4YA [Q = N(OH)CHO, CONH(OH); Y = CO, CS, SO, SO₂; R₁ = H, alkyl, haloalkyl, OH, alkoxy, alkenyloxy, halo, amino, alkylamino, dialkylamino; R₂ = (substituted) alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkylalkyl, aralkyl, heterocyclylalkyl, aminoalkyl; R₃R₄ = atoms to form a (substituted) saturated 4-7 membered heterocyclic ring which may be fused to a second carbocyclic or heterocyclic ring; A = amino, R₅, OR₅; R₅ = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, alkoxyalkyl, alkylthioalkyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl, etc.], were prepared. Thus, 3-N-benzoyloxyformylamino-(2R)-cyclopentylmethylpropionic acid in DMF at 0° was treated with EDAC and HOBt followed by stirring for 15 min. and addition of 1,2-diazacyclohexane hydrochloride and diisopropylethylamine; the mixture was kept at 0° for 1 h and warmed to room temperature and left for 5 h to give 65% N-benzoyloxy-N-[(2R)-cyclopentylmethyl-3-oxo-3-(tetrahydropyridazin-1-yl)propyl]formamide. The latter in CH₂Cl₂ at 0° was treated with 2-furoyl chloride and diisopropylethylamine followed by stirring for 30 min. and warming to room temp and kept for 16 h to give 89% diacyl derivative, which was hydrogenolyzed in MeOH over Pd/C to give 100% (2R)-cyclopentylmethyl-3-[2-(furan-2-carbonyl)tetrahydropyridazin-1-yl]-3-oxopropylformamide. This inhibited *S. pneumoniae* with a min. inhibitory concentration of 0.5-2 µg/mL.

IT Infection

(bacterial, treatment; preparation of acylpyridazines and acylpyrazolidines as antibacterial agents)

IT Antibacterial agents

Drug delivery systems

Human

(preparation of acylpyridazines and acylpyrazolidines as antibacterial

agents)

IT 706778-35-0P 706778-36-1P 706778-37-2P
 706778-38-3P 706778-39-4P 706778-40-7P
 706778-41-8P 706778-42-9P 706778-43-0P
 706778-44-1P 706778-45-2P 706778-46-3P
 706778-47-4P 706778-48-5P 706778-49-6P
 706778-50-9P 706778-51-0P 706778-52-1P
 706778-53-2P 706778-54-3P 706778-55-4P
 706778-56-5P 706778-57-6P 706778-58-7P
 706778-59-8P 706778-60-1P 706778-61-2P
 706778-62-3P 706778-63-4P 706778-64-5P
 706778-65-6P 706778-66-7P 706778-67-8P
 706778-68-9P 706778-69-0P 706778-70-3P
 706778-71-4P 706778-73-6P 706778-74-7P
 706778-75-8P 706778-76-9P 706778-77-0P
 706778-78-1P 706778-79-2P 706778-80-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of acylpyridazines and acylpyrazolidines as antibacterial
 agents)

IT 103-71-9, Phenyl isocyanate, reactions 527-69-5, 2-Furoyl chloride
 700-87-8, 2-Methoxyphenyl isocyanate 4285-42-1, N-Methyl-N-
 phenylcarbamoyl chloride 16588-74-2, 3,5-Bistrifluoromethylphenyl
 isocyanate 57699-91-9 89990-53-4 301684-75-3 325796-41-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of acylpyridazines and acylpyrazolidines as antibacterial
 agents)

IT 706778-81-6P 706778-82-7P 706778-83-8P 706778-84-9P 706778-85-0P
 706778-86-1P 706778-87-2P 706778-88-3P 706778-89-4P 706778-90-7P
 706778-91-8P 706778-92-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of acylpyridazines and acylpyrazolidines as antibacterial
 agents)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.53	172.17

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.75	-0.75

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 07:02:45 ON 31 OCT 2006